Drug Trial Radar · NCT01140217
Efficacy and Safety Study of Norethindrone Acetate Transdermal Delivery System in Contraception
Last checked: Nov 20, 2026Latest source record: Sep 19, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,659
Actual
Start
May 2010
Primary completion
Mar 2012
Study completion Mar 2012
Sponsor
- Lead sponsor
- Watson PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jun 9, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- Who can join
- Female only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine whether NEA TDS is effective in the prevention of pregnancy. The safety of this product will also be evaluated.
Conditions
- Contraceptive Usage
Interventions
Norethindrone AcetateDrug
Norethindrone Acetate Transdermal Delivery System
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pregnancy RateTime frame: 1 year
Locations
53 sites in 1 country. Site status is shown where the registry gives one.
Watson Investigational Site
Birmingham, Alabama
Watson Investigational Site
Mobile, Alabama
Watson Investigational Site
Montgomery, Alabama
Watson Investigational Site
Chandler, Arizona
Watson Investigational Site
Little Rock, Arkansas
Watson Investigational Site
Garden Grove, California
Watson Investigational Site
La Mesa, California
Watson Investigational Site
San Diego, California
Watson Investigational Site
Denver, Colorado
Watson Investigational Site
Newark, Delaware
Watson Investigational Site
Washington D.C., District of Columbia
Watson Investigational Site
Aventura, Florida
Watson Investigational Site
Daytona Beach, Florida
Watson Investigational Site
Jacksonville, Florida
Watson Investigational Site
Lake Worth, Florida
Watson Investigational Site
Miami, Florida
Watson Investigational Site
North Miami, Florida
Watson Investigational Site
Pinellas Park, Florida
Watson Investigational Site
Sarasota, Florida
Watson Investigational Site
Atlanta, Georgia
Watson Investigational Site
Decatur, Georgia
Watson Investigational Site
Sandy Springs, Georgia
Watson Investigational Site
Savannah, Georgia
Watson Investigational Site
Chicago, Illinois
Watson Investigational Site
Overland Park, Kansas
Watson Investigational Site
Marrero, Louisiana
Watson Investigational Site
New Orleans, Louisiana
Watson Investigational Site
Haverhill, Massachusetts
Watson Investigational Site
Ann Arbor, Michigan
Watson Investigational Site
Kalamazoo, Michigan
Watson Investigational Site
Edina, Minnesota
Watson Investigational Site
Las Vegas, Nevada
Watson Investigational Site
Lawrenceville, New Jersey
Watson Investigational Site
Albuquerque, New Mexico
Watson Investigational Site
New York, New York
Watson Investigational Site
Chapel Hill, North Carolina
Watson Investigational Site
New Bern, North Carolina
Watson Investigational Site
Raleigh, North Carolina
Watson Investigational Site
Cleveland, Ohio
Watson Investigational Site
Columbus, Ohio
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.